GlassScriptPhysician profile
Majla Husic
NPI 1083379119
$569.62
in general payments reported to CMS, 2019-2025
14 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $252 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $569.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $110.66 | 2024 | Voquezna |
| Novo Nordisk INC | $103.86 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $60.56 | 2024-2025 | Airsupra, Breztri |
| Amgen INC. | $58.45 | 2024-2025 | Evenity, Prolia |
| Viatris Specialty LLC | $43.28 | 2025 | Yupelri |
| Astellas Pharma US INC | $29.69 | 2025 | Veozah |
| Dexcom, INC. | $25.77 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $25.00 | 2025 | |
| Hologic Sales and Service, LLC | $23.99 | 2025 | Aptima, Thinprep 2000 Processor |
| Janssen Pharmaceuticals, INC | $20.31 | 2025 | Spravato |
| Shield Therapeutics INC | $19.88 | 2024 | |
| Organon LLC | $17.26 | 2025 | Nexplanon |
| Corium, LLC | $15.86 | 2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $15.05 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Majla Husic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.